(Press-News.org) April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.
Among GT-3 patients, SVR12 rates were highest in those receiving SOF+PEG/RBV for 12 weeks (93%) as compared to SOF+RBV for 24 (84%, p = 0.008) or 16 weeks (71%, p END
Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients
Results from the ground-breaking new BOSON study
2015-04-25
ELSE PRESS RELEASES FROM THIS DATE:
Alcohol use disorders - stronger predictor of mortality than chronic hepatitis C virus infection
2015-04-25
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.
The study found that chronic HCV infection has a limited impact on mortality, unless the patient also has other severe comorbidities, such as HIV infection, cancer or chronic kidney disease. In contrast, those with AUDs are at significant risk of death with a higher ...
Sofosbuvir/daclatasvir combination effective treatment for difficult-to-treat hep C patients
2015-04-25
April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations.
Overall, the sustained virologic response rate at 4 weeks (SVR4) for SOF/DCV was 81.6% after 12 weeks of treatment and 93.9% ...
DCV, SOF & RBV comb. effective/tolerated in HCV with adv, cirrhosis / post-transplant recurrence
2015-04-25
April 25, 2015, Vienna , Austria: Phase 3 results presented today at The International Liver Congress™ 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. Sustained virologic response rates at 12 weeks (SVR12) were >90% in patients with Child-Pugh class A or B cirrhosis but lower in Child-Pugh class C. SVR12 was achieved by 94% of liver transplant recipients with HCV recurrence.
ALLY-1 ...
Drinking just 1 or 2 alcoholic drinks a day linked to liver disease
2015-04-25
April 25, 2015, Vienna, Austria: According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver CongressTM 2015 has shown the significant influence of daily drinking on this disease burden. New data shows that the cirrhosis burden caused by alcohol increased by 11.13% when moving from the moderate to heavy daily drinking (up to one drink/day for women; two drinks/day for men) classification (p END ...
Prelim. safety findings: IFN-free DAA comb. with dasabuvir in chronic HCV patients
2015-04-25
April 25, 2015, Vienna, Austria: Preliminary data from an ongoing study revealed today at The International Liver Congress™ 2015 suggest that a combination of three direct-acting antivirals (DAAs) plus dasabuvir is well tolerated in patients with severe renal impairment or end-stage renal disease when used either with or without ribavirin. In addition, the combination led to rapid hepatitis C viral load suppression with no virological failures seen in the preliminary data from the ongoing open-label study.
In the study, treatment naïve non-cirrhotic adults ...
Researchers highlight need for better evidence to guide EU efforts to increase hep B+C testing
2015-04-25
April 25, 2015, Vienna, Austria: The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver CongressTM 2015.
The systematic review concluded that the current evidence base on hepatitis B and C testing appears to be lacking in many European countries. At present it is informed primarily by published articles and conference abstracts from just 6 out of 53 member countries of ...
Use of pocket-sized ultrasound device reduces need for further testing in clinical settings
2015-04-25
April 25, 2015, Vienna, Austria: Results from a study presented today at The International Liver Congress™ 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting.
The study evaluated the effectiveness of the PUD when testing for the following conditions: biliary-duct dilation, gallstones, ascites, splenomegaly, pleural effusion, pericardial effusion, urinary retention, urinary stones, abdominal mass and aortic aneurysm.
PUDs offer a comparable performance ...
Hepatitis C screening essential to help catch patients with advanced liver fibrosis
2015-04-25
April 25, 2015, Vienna, Austria: Study results presented today at The International Liver Congress™ 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.
Most individuals with HCV remain asymptomatic, which makes the diagnosis difficult. The study authors used the hypothesis that individuals whose HCV is not diagnosed are less likely to have advanced fibrosis than those who have been diagnosed. They then compared liver fibrosis between respondents of the ...
Combined brachytherapy techniques should be 'benchmark' for cervical cancer treatment
2015-04-25
Barcelona, Spain: The first large international study to investigate the late side-effects of a combination of two forms of brachytherapy to treat cervical cancer has shown that the technique successfully delivers higher radiation doses to the tumour without an increase in treatment-related problems afterwards.
Brachytherapy is a type of internal radiotherapy that involves putting a radioactive source close to, or in the tumour. It is often performed after a CT or MRI scan has pinpointed the exact position of the cancer, so that the radiation treatment can be targeted ...
Mental disorders don't predict future violence
2015-04-25
Depression is not linked to violence among males
Some delinquent youth with current psychiatric illness may be violent
Providing treatment could reduce violence
CHICAGO --- Most psychiatric disorders - including depression -- do not predict future violent behavior, according to new Northwestern Medicine longitudinal study of delinquent youth. The only exception is substance abuse and dependence.
"Our findings are relevant to the recent tragic plane crash in the French Alps. Our findings show that no one could have predicted that the pilot - who apparently ...
LAST 30 PRESS RELEASES:
Advanced nuclear magnetic resonance technique developed to reveal precise structural and dynamical details in zeolites
Advancing performance assessment of a spectral beam splitting hybrid PV/T system with water-based SiO2 nanofluid
Researchers realize target protein stability analysis by time-resolved ultraviolet photodissociation mass spectrometry
Oxygen vacancies mediated ultrathin Bi4O5Br2 nanosheets as efficient piezocatalyst for synthesis of H2O2 from pure water
Warming and exogenous organic matter input affected temperature sensitivity and microbial carbon use efficiency of agricultural soil respiration on the Qinghai-Tibet Plateau
Eco-friendly glue designed by Cal Poly, Geisys Ventures team earns industry 'Innovation Award'
From dreams to reality: unveiling the ideal in situ construction method for lunar habitats and paving the way to Moon colonization
From theory to practice: Study demonstrates high CO2 storage efficiency in shale reservoirs using fracturing technology
What women want: Female experiences to manage pelvic pain
Study finds ChatGPT shows promise as medication management tool, could help improve geriatric health care
Heart failure, not stroke is the most common complication of atrial fibrillation
Antipsychotics for dementia linked to more harms than previously acknowledged
Health improvements occurred worldwide since 2010 despite COVID-19 pandemic, but progress was uneven
Mind the gender gap – Met police least trusted by women
Surrey engineers help Mauritius spot illegal fishing from space
Opioid dependence remains high but stable in Scotland, new surveillance report finds
Protecting brain cells with cannabinol
Calorie restriction study reveals complexities in how diet impacts aging
Atom-by-atom: Imaging structural transformations in 2D materials
How 3D printers can give robots a soft touch
Rice alumna wins prestigious merit-based fellowship for new Americans
International group runs simulations capable of describing South America's climate with unprecedented accuracy
Researchers find that accelerated aging biology in the placenta contributes to a rare form of pregnancy-related heart failure
Vibrations of granular materials: an everyday scientific mystery
UW–Madison biochemist wins prestigious forestry prize for discoveries that support sustainable energy and product innovations
New SPECT/CT technique shows impressive biomarker identification, offers increased access for prostate cancer patients
Study identifies new metric for diagnosing autism
Researchers create new AI pipeline for identifying molecular interactions
Clearing the air: Wind farms more land efficient than previously thought
Fracking the future: how Congolese oil extraction has shaped its history and its fate
[Press-News.org] Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patientsResults from the ground-breaking new BOSON study